{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:02:53Z","timestamp":1785423773493,"version":"3.56.0"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R01AI179827, 1R21AI148096"],"award-info":[{"award-number":["1R01AI179827, 1R21AI148096"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","award":["KANT23G0"],"award-info":[{"award-number":["KANT23G0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NTM Education and Research funding support from the University of Texas at Tyler"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Treatment of\n                      <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                      (MAB) pulmonary diseases is challenging due to intrinsic resistance to many antibiotics and requires prolonged intravenous therapy with drugs that have severe side effects. The treatment guidelines include tetracyclines as part of the combination. We tested a 3rd generation tetracycline, eravacycline, for its potential role in MAB pulmonary disease. Eravacycline minimum inhibitory concentration (MIC) (ATCC#19977 strain and 59 clinical isolates) ranged between 0.0075 and 0.3 mg\/L, and the MIC\n                      <jats:sub>50<\/jats:sub>\n                      and MIC\n                      <jats:sub>90<\/jats:sub>\n                      were 0.15 and 0.3 mg\/L, respectively. In the static concentration-response studies, eravacycline killed 5.58 + 0.34 log\n                      <jats:sub>10<\/jats:sub>\n                      CFU\/mL MAB, and EC\n                      <jats:sub>50<\/jats:sub>\n                      (concentration associated with 50% of the maximal effect [\n                      <jats:italic toggle=\"yes\">E<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      ]) was 0.05 \u00b1 0.01 mg\/L. In the hollow fiber system model of\n                      <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                      (HFS-MAB), examining eight eravacycline human-equivalent lung exposures, the ratio of area under the concentration-time curve to MIC (AUC\n                      <jats:sub>0-24<\/jats:sub>\n                      \/MIC) of 3,588 was identified as EC\n                      <jats:sub>80<\/jats:sub>\n                      or the optimal exposure target for MAB kill. The probability of target attainment even with eravacycline doses of 4 mg\/kg twice a day (8 mg\/kg\/day) falls below 90% at an MIC of 0.125 mg\/L, and the cumulative fraction of response was only 30.56% in the 10,000 virtual patient trial. In summary, a MIC pattern does not accurately inform whether a tetracycline (in this study, eravacycline) has good efficacy, which must be determined using preclinical models applying a pharmacokinetics\/pharmacodynamics study design. The HFS-MAB results suggest that, despite low MICs, the probability of better therapeutic outcomes with eravacycline is limited.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        Treatment of\n                        <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                        (MAB) pulmonary diseases is challenging due to intrinsic resistance to many antibiotics. The ATS\/IDSA guidelines include tetracyclines as part of the combination. Eravacycline is a new tetracycline approved for the treatment of complicated intra-abdominal bacterial infections with better tolerability and low gastrointestinal adverse events compared to tigecycline. We performed an eravacycline pharmacokinetics (PK)-pharmacodynamics (PD) study for dose optimization with respect to the MAB pulmonary disease mimicking the intrapulmonary PKs in the hollow fiber model system of MAB (HFS-MAB). While eravacycline MICs and static concentrations suggest great potential and even activity better than omadacycline and tigecycline, the drug only killed 0.56 log\n                        <jats:sub>10<\/jats:sub>\n                        CFU\/mL below stasis in the HFS-MAB. Monte Carlo simulation experiments suggested that optimal doses for MAB pulmonary disease are likely in the range that would not be tolerated by patients.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.03432-25","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T14:04:52Z","timestamp":1765375492000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Eravacycline pharmacokinetics\/pharmacodynamics in the hollow fiber system model of\n                    <i>Mycobacterium abscessus<\/i>\n                    lung disease"],"prefix":"10.1128","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-5673","authenticated-orcid":true,"given":"Sanjay","family":"Singh","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avneesh","family":"Shrivastava","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunavanthi D.","family":"Boorgula","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Long","sequence":"additional","affiliation":[{"name":"Advanta Genetics","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Robbins","sequence":"additional","affiliation":[{"name":"Advanta Genetics","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-8012","authenticated-orcid":true,"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"IMPI Biotech Consortium Inc.","place":["Tateguru, Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-8851","authenticated-orcid":true,"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine","place":["Tyler, USA"]},{"id":[{"id":"https:\/\/ror.org\/01sps7q28","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Cellular and Molecular Biology, The University of Texas Health Science Centre at Tyler","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201501-015OI"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1125"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1874ST"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2203.150828"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku062"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106847"},{"key":"e_1_3_3_8_2","unstructured":"Tetraphase Pharmaceuticals Inc. 2018. XERAVA (eravacycline) for injection for intravenous use Initial U.S. approval: 2018 reference ID: 4312367. Tetraphase Pharmaceuticals Inc. Watertown MA"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00470-19"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00718-23"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00689-22"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02351-23"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa071"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ460"},{"key":"e_1_3_3_15_2","unstructured":"Food and Drug Administration. 2022. Pulmonary tuberculosis: developing drugs for treatment. Guidance for industry. Department of Health and Human Services Rockville MD. https:\/\/www.fda.gov\/media\/87194\/download."},{"key":"e_1_3_3_16_2","unstructured":"Critical Path Institute. 2018. Hollow fiber system model of tuberculosis (HFS-TB): a laboratory manual to guide system engineering study design and execution. Critical Path Institute Tucson AZ. https:\/\/c-path.org\/wp-content\/uploads\/2018\/06\/2018_06_13_HFS-TB_LabManual_v1.0.pdf."},{"key":"e_1_3_3_17_2","volume-title":"Qualification opinion. in-vitro hollow fiber system model of tuberculosis (HSF-TB)","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. 2015. Qualification opinion. in-vitro hollow fiber system model of tuberculosis (HSF-TB). Agency EM, EMA, London, UK."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ484"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01065-24"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03112-15"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz267"},{"key":"e_1_3_3_22_2","unstructured":"Food and Drug Administration. 2018. NUZYRA (omadacycline) for injection for intravenous use; NUZYRA (omadacycline) tablets for oral use."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad335"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab002"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2023.e01703"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02282-15"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02821-15"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00990-16"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae601"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtldopen.25.0173"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf405"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00829-13"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad545"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107204:107204"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac068"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw471"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz523"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.01.001"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00240-16"},{"key":"e_1_3_3_42_2","volume-title":"CLSI standard M24","author":"Woods GL","year":"2018","unstructured":"Woods GL, Cengenack NL, Lin G, Brown-Elliot BA, Cirillo DM, Conville PC, DEsmond EP, Killian SB, Parrish MM, Pfeltz R, Richer E, Turnidge JD. 2018. Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. In CLSI standard M24, 3rd ed. Clinical and Laboratory Standards Institute, Institute CLS, Pittsburgh, PA.","edition":"3"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01174-18"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.52783\/jchr.v13.i6.2037"},{"key":"e_1_3_3_45_2","unstructured":"Certara USA. 2020. Phoenix WinNonlin version 8.1. Certara USA Inc. Princeton NJ. Available from: https:\/\/www.certara.com\/software\/phoenix-pkpd"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03432-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03432-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:09:03Z","timestamp":1767708543000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.03432-25"}},"subtitle":[],"editor":[{"given":"Aude A.","family":"Ferran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"alternative-id":["10.1128\/spectrum.03432-25"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.03432-25","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"2025-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03432-25"}}